Bulletin of Semashko National Research Institute of Public HealthBulletin of Semashko National Research Institute of Public Health2415-84102415-8429FSSBI «N.A. Semashko National Research Institute of Public Health»284310.69541/NRIPH.2024.03.016Научная статьяAlgorithm for calculating the economic impact of introducing neonatal screening for rare diseasesKomarovIlya A.iliya_komarov@mail.ruhttps://orcid.org/0000-0002-1518-184XAlexandrovaOxana Yu.aou18@mail.ruhttps://orcid.org/0000-0002-0761-1838N. A. Semashko National Research Institute of Public Health01102024310310727052025Copyright © 2025,2025<p>In recent years, in the Russian Federation, the program of state guarantees of free medical care to citizens has included expanded neonatal screening, including for rare diseases. At the same time, it is important to understand the economic impact of this initiative on the state budget. On the one hand, timely detection of diseases allows for better control in their treatment. On the other hand, this will require more healthcare resources and, as a result, additional budgetary expenses. The purpose of the study is to develop an algorithm for calculating the economic impact of introducing neonatal screening for rare diseases. The regulatory documents regulating the provision of medical care, as well as neonatal screening for rare diseases, were analyzed. As an example for the development of the algorithm, a study was used to assess the socio-economic effectiveness of neonatal screening for spinal muscular atrophy in the Russian Federation, as well as examples of domestic pharmacoeconomic studies. The main types of costs that need to be assessed in the economic analysis of the consequences of introducing screening are identified. Approaches to their accounting are presented based on existing regulatory documents.</p>rare diseasesorphan drugschildrenexpanded neonatal screeninghealthcareState Guarantee Programредкие болезниорфанные лекарственные препаратыдетирасширенный неонатальный скринингздравоохранениеПрограмма государственных гарантий1.Komarov I.A., Sokolov А.А., Aleksandrova O.Yu. Issues of high-technology medical service providing for patients with orphan diseases. Health care Standardization Problems. [Problemy standartizatsii v zdravookhranenii]. 2019;(7—8):63—72 (in Russian). DOI: 10.26347/1607-2502201907-08063-0722.3.Komarov I.A., Aleksandrova O.Yu., Nagibin O.A. Current organization of drug maintenance for certain patient groups. Role of drug lists. Healthcare Manager. [Menedzher zdravookhraneniya]. 2019;(5):53—60 (in Russian).4.5.Komarov I.A., Malakhova A.R., Vasilyeva T.P. et al. Socioeconomic efficiency of neonatal screening for spinal muscular atrophy in the Russian Federation. Neuromuscular Diseases. [Nervno-myshechnye bolezni]. 2023;13(3):25—32. (in Russian). DOI: 10.17650/2222-8721-2023-13-3-25-326.7.Kulikov A.Yu., Komarov I.A. Pharmacoeconomic analysis of the drug Beyodaime (pertuzumab + trastuzumab [set]) in the treatment of metastatic breast cancer in patients with the HER2+ form of the disease. Pharmacoeconomics: Theory and Practice. [Farmakoekonomika: teoriya i praktika]. 2015;3(2):32—9 (in Russian).8.9.Kulikov A.Yu., Komarov I.A. Pharmacoeconomic study of the use of bronchodilators of the M-anticholinergic group (Spiriva® and Atrovent®) in the treatment of chronic obstructive pulmonary disease. Farmakoekonomika. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. [Sovremennaya farmakoekonomika i farmakoepidemiologiya]. 2012;(3):20—6 (in Russian).10.11.Kulikov A.Yu., Komarov I.A. Analysis of the effectiveness of the use of Cerebrolysin in the treatment of acute ischemic cerebrovascular accident based on an assessment of real clinical practice in the Russian Federation. Modern Organization of Drug Supply. [Sovremennaya organizatsiya lekarstvennogo obespecheniya]. 2013;(2):31—7 (in Russian).